#HARPOON THERAPEUTICS STOCK LICENSE#

Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. was incorporated in 2015 and is headquartered in South San Francisco, California.

to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors.

#HARPOON THERAPEUTICS STOCK LICENSE#

The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.

Harpoon therapeutics stock